GeneDx Holdings Corp. updated earnings guidance for the year 2024. For the year, the company now expects revenues to be between $235 million and $245 million (previous guidance was $220 million to $230 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.01 USD | -4.65% | +27.54% | +809.45% |
Jun. 05 | GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients | CI |
Apr. 30 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+809.45% | 654M | |
-22.13% | 7.9B | |
+76.16% | 4.53B | |
+8.56% | 2.78B | |
-2.80% | 2.64B | |
-50.41% | 1.99B | |
-19.59% | 1.66B | |
-20.07% | 1.49B | |
+19.31% | 1.23B | |
-45.78% | 1.1B |
- Stock Market
- Equities
- WGS Stock
- News GeneDx Holdings Corp.
- GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024